No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed
Source: SeekingAlpha
2025-05-09 09:38:32 ET
Summary
- IOVA's Q1'25 product revenue was $49.3M, impacted by production facility maintenance; however, Q2'25 estimates for infusions imply weak growth, despite not being impacted by production.
- Replimune's RP1 could be approved in July 2025, providing market competition for melanoma patients.
- Obsidian Therapeutics will present phase 1 data from the Agni-01 trial of their cell therapy OBX-115 at ASCO 2025 on June 2.
Read the full article on Seeking Alpha
For further details see:
No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
10.12% G/L:
$5.1199 Last:
764,176 Volume:
$4.90 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
